Galapagos to present new atalanta-1 car-t data at eha 2025, highlighting low toxicity and rapid, decentralized delivery of fresh, early-memory-enriched glpg5101 in r/r nhl

Data reported from the ongoing atalanta-1 phase 1/2 study in a heavily pretreated relapsed refractory non-hodgkin's lymphoma (r/r nhl) patient population demonstrate low rates of high-grade toxicities

CAR Ratings Summary

CAR Quant Ranking